"Cocktail" Approaches and Strategies in Drug Development: Valuable Tool or Flawed Science?

Journal of Clinical Pharmacology

Volumn 44, Issue 2, 2004, Pages 120-134

  Zhou, Honghui ^a   Tong, Zeen ^a   McLeod, James F ^b  

^a PFIZER INC   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

"Cocktail"; CYP; Drug drug interaction

Indexed keywords

CAFFEINE; CARBAMAZEPINE; CHLORZOXAZONE; CLONIDINE; COUMARIN; DAPSONE; DEBRISOQUINE; DEXTROMETHORPHAN; DICLOFENAC; DIGITOXIN; DRUG METABOLIZING ENZYME; LIDOCAINE; MEPHENYTOIN; METOPROLOL; MIDAZOLAM; MINOXIDIL; OMEPRAZOLE; PHENYTOIN; PROGUANIL; QUINIDINE; SPARTEINE; SULFADIMIDINE; THEOPHYLLINE; THIAMAZOLE; TOLBUTAMIDE; TRIMETHADIONE; UNINDEXED DRUG; VALPROIC ACID; VITAMIN K GROUP; WARFARIN;

CLINICAL PATHWAY; DRUG ANTAGONISM; DRUG COCKTAIL; DRUG COMPETITION; DRUG EFFICACY; DRUG METABOLISM; DRUG MIXTURE; DRUG RESEARCH; DRUG SAFETY; ENZYME ACTIVITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PHENOTYPE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT;

ANIMALS; CLINICAL TRIALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; GENOTYPE; HUMANS; METABOLIC CLEARANCE RATE; PHARMACOGENETICS; PHARMACOLOGY, CLINICAL; RESEARCH DESIGN; SUBSTRATE SPECIFICITY;

EID: 1642494659     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003261333     Document Type: Review

References (102)

1. Schellens JHM, Van Der Wart JHF, Danhof M, Van Der Velde EA, Breimer DD: Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a "cocktail" approach. Br J Clin Pharmacol 1988;26:373-384.
2. Back DJ, Tija J, Monig H, Ohnhaus EE, Park BK: Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. Eur J Clin Pharmacol 1988;34:157-163.
3. Breimer DD, Schellens JHM: A "cocktail" strategy to assess in vivo oxidative drug metabolism in humans. Trends Pharmacol Sci 1990;11:223-225.
4. Tucker GT, Houston JB, Huang S-M: Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Clin Pharmacol Ther 2001;70(2):103-114.
5. Breimer DD: Interindividual differences in drug disposition: clinical implications and methods of investigation. Clin Pharmacokinet 1983;8:371-377.
6. Paolini M, Biagi GL, Bauer C, Cantelli-Forti G: Cocktail strategy: complications and limitations. J Clin Pharmacol 1993;33:1011-1012.
7. Colburn WA: Another perspective on the cocktail strategy: "two glasses of wine or a six pack." J Clin Pharmacol 1995;35:655-657.
8. Frye RF, Matzke GR, Adedoyin A, Porter JA, Branch RA: Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clin Pharmacol Ther 1997;62:365-376.
9. Streetman DS, Bleakley JF, Kim JS, Nafziger AN, Leeder JS, Gaedigk A, et al: Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail." Clin Pharmacol Ther 2000;68:375-383.
10. Zhu B, Ou-Yang DS, Chen XP, Huang SL, Tan ZR, Zhou HH: Assessment of cytochrome P450 activity by a five-drug cocktail approach. Clin Pharmacol Ther 2001;70:455-461.
11. Scott RJ, Palmer J, Lewis IAS, Pleasance S: Determination of a "GW Cocktail" of cytochrome P450 probe substrate and their metabolites in plasma and urine using automated solid phase extraction and fast gradient liquid chromatography tandem mass spectrometry. Rapid Commun Mass Spectrom 1999;13:2305-2319.
12. Wang Z, Gorski JC, Hamman MA, Huang S-M, Lesko LJ, Hall S: The effects of St. John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001;70:317-326.
13. Goldberg RM, Mabee J, Chan L, Wong S: Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med 1996;14(5):447-450.
14. Kohler GI, Bode-Boger SM, Busse R, Hoopmann M, Welte T, Boger RH: Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 2000;38(11):504-513.
15. Tucker GT, Houston JB, Huang SM: Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Clin Pharmacol Ther 2001;70(2):103-114.
16. Huang SM, Honig P, Lesko LJ, Temple R, Williams R: An integrated approach to assessing drug-drug interactions: a regulatory perspective, in: Rodrigues AD (ed.), Drug-Drug Interactions. New York: Marcel Dekker, 2002.
17. Huang SM, Lesko LJ, Williams RL: Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues. J Clin Pharmacol 1999;39:1006-1014.
18. Rodrigues AD, Winchell GA, Dobrinska MR: Use of in vitro drug metabolism data to evaluate metabolic drug-drug interactions in man: the need for quantitative databases. J Clin Pharmacol 2001;41:368-373.
19. Davit B, Reynolds K, Yuan R, Ajayi F, Conner D, Fadiran E, Gillespie B, et al: FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling. J Clin Pharmacol 1999;39:899-910.
20. Food and Drug Administration: FDA Guidance for Industry: Drug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies in Vitro. Rockville, MD: FDA, April 1997.
21. Food and Drug Administration: FDA Guidance for Industry: In Vivo Drug Metabolism/Drug Interaction Studies-Study Design, Data Analysis, and Recommendations for Dosing and Labeling. Rockville, MD: FDA, 1999.
22. Kuhlmann J, Mück W: Clinical-pharmacological strategies to assess drug interaction potential during drug development. Drug Safety 2001;24(10):715-725.
23. Food and Drug Administration: FDA Guidance for Industry: Population Pharmacokinetics. Rockville, MD: FDA, 1999.
24. New York State Assembly Bill A8087, May 27, 1997.
25. Dierks EA, Stams KR, Lim HK, Cornelius G, Zhang H, Ball SE: A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab Disp 2001;29:23-29.
26. Adedoyin A, Frye RF, Mauro K, Branch RA: Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail. Br J Clin Pharmacol 1998;46:215-219.
27. Adedoyin A, Stiff DD, Smith DC, Romkes M, Bahnson RC, Day R, et al: All-trans-retinoic acid madulation of drug-metabolizing enzyme activities: investigation with selective metabolic drug probes. Cancer Chemother Pharmacol 1998;41:133-139.
28. Sigusch H, Henschel L, Hoffmann A: Investigation of nifedipine and verapamil effect on transformation and indocyanine green kinetics. Gastroenterol J 1991;51:33-36.
29. Shedlofsky SI, Israel BC, McClain CJ, Hill DB, Blouin RA: Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J Clin Invest 1994;94:2209-2214.
30. Shedlofsky SI, Israel BC, Tosheva R, Blouin RA: Endotoxin depresses hepatic cytochrome P450-mediated drug metabolism in women. Br J Clin Pharmacol 1997;43:627-632.
31. Israel BC, Blouin RA, McIntyre W, Shedlofsky SI: Effects of interferon-α monotherapy on hepatic drug metabolism in cancer patients. Br J Clin Pharmacol 1993;36:229-235.
32. Frye RF, Schneider VM, Frye CS, Feldman AM: Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. J Card Fail 2002;8(5):315-319.
33. Schellens JHM, Ghabrial H, van der Wart HHF, Bakker EN, Wilkinson GR, Breimer DD: Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans. Clin Pharmacol Ther 1991;50:520-528.
34. Bruce MA, Hall SD, Haehner-Daniels BD, Gorski JC: In vivo effect of clarithromycin on multiple cytochrome P450s. Drug Metab Disp 2001;29(7):1023-1028.
35. Atiba JO, Blaschke TF, Wilkinson GR: Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquine. Br J Clin Pharmacol 1989;28:161-165.
36. Lanchote VL, Ping WC, Santos SRCJ: Influence of renal failure on cytochrome P450 activity in hypertensive patients using a "cocktail" of antipyrine and nifedipine. Eur J Clin Pharmacol 1996;50:83-89.
37. May CB, Csuka ME, Lupoli S, Wilkinson GR, Branch RA: Activity of oxidative routes of metabolism of debrisoquin, mephenytoin, and dapsone is unrelated to the pathogenesis of vinyl chloride-induced disease. Clin Pharmacol Ther 1992;52:659-667.
38. Lower GM: Concepts in causality: chemically induced human bladder cancer. Cancer 1982;49:1056-1066.
39. Weisburger JH, Weisburger EK: Biochemical formation and pharmacology, toxicology and pathological properties of hydroxylamines and hydroxamic acids. Pharmacol Rev 1973;25:1-66.
40. Branch RA, Chern HD, Adedoyin A, Romkes-Sparks M, Lesnick TG, Persad R, et al: The procarcinogen hypothesis for bladder cancer: activities of individual drug metabolizing enzymes as risk factors. Pharmacogenetics 1995;5:S97-S102.
41. Truckenbrodt J, Kraul H, Huster A, Töpfer R, Henschel L, Hoffmann A, et al: Investigation of biotransformation capacity in chronic liver disease by simultaneous application of various drugs. Gastroenterol J 1990;50:179-182.
42. Schellens JHM, Soons PA, van der WART JHF, Hoevers JW, Breimer DD: Lack of pharmacokinetic interaction between nifedipine, sparteine and phenytoin in man. Br J Clin Pharmacol 1991;31:175-178.
43. Endres HE, Henschel L, Merkel U, Hippius M, Hoffmann A: Lack of pharmacokinetic interaction between dextromethorphan, coumarin and mephenytoin in man after simultaneous administration. Pharmazie 1996;51(1):46-51.
44. Sanz EJ, Villen T, Alm C, Bertilsson L: S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 1989;45:495-499.
45. Guttendorf RJ, Britto M, Blouin RA, Foster TS, John W, Pittman KA, et al: Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism. Br J Clin Pharmacol 1990;29:373-380.
46. Evans WE, Relling MV, Petros WP, Meyer WH, Mirro J, Crom WR: Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children. Clin Pharmacol Ther 1989;45:568-573.
47. Tennezé L, Verstuyft C, Becquemont L, Poirier JM, Wilkinson GR, Funck-Brentano C: Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination. Clin Pharmacol Ther 1999;66:582-588.
48. Berthou F, Goasduff T, Lucas D, Dréano Y, Le Bot MH, Ménez JF: Interaction between two probes used for phenotyping cytochrome P4501A2 (caffeine) and P4502E1 (chlorzoxazone) in humans. Pharmacogenetics 1995;5:72-79.
49. Palmer JL, Scott RJ, Gibson A, Dickins M, Pleasance S: An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). Br J Clin Pharmacol 2001;52:555-561.
50. Smith BL, Sarnoski TP, Dennis S, Luke DR: Failure of predicted creatinine clearance equations in HIV-seropositive patients. Int J Clin Pharmacol Ther Toxicol 1992;30:394-399.
51. Brailska M: Clinical possibilities of a method for the simultaneous determination of the GFR and the ERBF using a "cocktail" of 169U-EDTA and 125I-hippuran. Vutr Boles 1976;15(5):56-60.
52. Gross AS, McLachlan AJ, Minns I, Beal JB, Tett SE: Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol. Br J Clin Pharmacol 2001;51:547-555.
53. Committee for Proprietary Medicinal Products (CPMP): Note for Guidance on the Investigation of Drug Interactions. London: CPMP, 1997.
54. Flockhart DA: Clinically used drugs metabolized by cytochrome P450 (updated 02/01/2002). Retrieved from http://medicine.iupui.edu/flockhart
55. Lee CR, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA: Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. J Clin Pharmacol 2003;43:84-91.
56. Thummel KE, Shen DD, Podoll T, Kunze KL, Trager WF, Hartwell P, et al: Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994;271:549-556.
57. Thummel KE, Shen DD, Podoll T, Kunze KL, Trager WF, Bacchi CE, et al: Use of midazolam as a human cytochrome CYP3A probe: II. Characterization of inter- and intra-individual hepatic CYP3A variability following liver transplantation. J Pharmacol Exp Ther 1994;271:557-566.
58. McCrea J, Prueksaritanont T, Gertz BJ, Carides A, Gillen L, Antonello S, et al: Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity. J Clin Pharmacol 1999;39:1212-1220.
59. Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Shirey CS, Gotschall R, et al: Quantification of intraindividual variability and influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. Pharmacogenetics 1998;8:403-410.
60. McCune JS, Lindley C, Decker JL, Williamson KM, Meadowcroft AM, Graff D, et al: Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan. J Clin Pharmacol 2001;41:723-731.
61. Peter R, Rocker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS: Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol 1990;3:566-573.
62. Lucas D, Berthou F, Girre C, Poitrenaud F, Menez JF: High-performance liquid chromatographic determination of chlorzoxazone and 6-hydroxychlorzoxazone in serum: a tool for indirect evaluation of cytochrome P4502E1 in humans. J Chromatogr 1993;622:79-86.
63. Kedderis GL, Batra R, Koop DR: Epoxidation of acrylonitrile by rat and human cytochromes P450. Chem Res Toxicol 1993;6:866-871.
64. Frye RF, Adedoyin A, Mauro K, Matzke GR, Branch RA: Use of chlorzoxazone as an in vivo probe of cytochrome P450 2E1: choice of dose and phenotypic trait measure. J Clin Pharmacol 1998;38:82-89.
65. Campbell ME, Grant DM, Inaba T, Kalow W: Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab Dispos 1987;15:237-249.
66. Denaro CP, Wilson M, Jacob P III, Benowitz NL: Validation of urine caffeine metabolite ratios with use of stable isotope-labeled caffeine clearance. Clin Pharmacol Ther 1996;59:284-296.
67. Tamminga WJ, Wemer J, Oosterhuis B, Wieling J, Touw DJ, de Zeeuw RA, et al: Mephenytoin as a probe for CYP2C19 phenotyping effect of sample storage, intra-individual reproducibility and occurrence of adverse events. Br J Clin Pharmacol 2001;51:471-474.
68. Beaudry F, Yves LE, Blanc JC, Coutu M, Brown NK: In vivo pharmacokinetic screening in cassette dosing experiments: the use of on-line Pprospekt liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry technology in drug discovery. Rapid Commun Mass Spectrom 1998;12(17):1216-1222.
69. Chauret N, Gauthier A, Martin J, et al: In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse. Drug Metab Dispos 1997;25:1130-1136.
70. Lin JH: Application and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab Dispos 1998;26:1202-1212.
71. Lave T, Coassolo P, Reigner B: Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations. Clin Pharmacokinet 1999;36:211-231.
72. Gonzalez FJ, Fernandez-Salguero P: The aryl hydrocarbon receptor: studies using the AHR-null mice. Drug Metab Dispos 1998;26:1194-1198.
73. Waxman DJ: P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptor CAR, PXR, and PPAR. Arch Biochem Biophys 1999;369:11-23.
74. Fuhr U: Induction of drug metabolising enzymes: pharmacokinetic and toxicological consequences in humans. Clin Pharmacokinet 2000;38:493-504.
75. Zhang X, Patel IH, Lalezari J, Badley A, Hawker N, Dorr A, et al: Assessment of metabolic inhibition potential of enfuvirtide using a 5-drug cocktail in HIV-1 infected patients. Clin Pharmacol Ther 2003;73(2):P81.
76. Shelepova T, Nafziger AN, Victory J, Kashuba AD, Rowland E, Zhang Y, et al: Effect of oral contraceptives (Ocs) on drug metabolizing enzymes (DMEs) as measured by the validated Cooperstown 5+1 cocktail (5+1). Clin Pharmacol Ther 2003;73(2):P14.
77. Gorski JC, Hall SD, Becker P, Affrime MB, Cutler DL, Haehner-Daniels B: In vivo effects of interleukin-10 on human cytochrome P450 activity. Clin Pharmacol Ther 2000;67:32-43.
78. Tanaka E, Ishikawa A, Misawa S: Changes in the metabolism of three model substrates catalyzed by different P450 isozymes when administered as a cocktail to the carbon tetrachloride-intoxicated rat. Xenobiotica 1995;25(10):1111-1118.
79. Relling MV, Crom WR, Pieper JA, Cupit GC, Rivera GK, Evans WE: Hepatic drug clearance in children with leukemia: changes in clearance of model substrates during remission-induction therapy. Clin Pharmacol Ther 1987;41:651-660.
80. Tanaka E, Ishikawa A, Misawa S: Changes in caffeine, lidocaine and trimethadione metabolism in carbon tetrachloride-intoxicated rats as assessed by a "cocktail" study. Pharmacol Toxicol 1994;75:150-153.
81. Brockmoller J, Roots I: Assessment of liver metabolic function: clinical implications. Clin Pharmacokinet 1994;27(3):216-248.
82. Setiabudy R, Kusaka M, Chiba K, Darmansjah I, Ishizaki T: Dapsone N-acetylation, metoprolol α-hydroxylation, and S-mephenytoin 4-hydroxylation polymorphisms in an Indonesian population: a cocktail and extended phenotyping assessment trial. Clin Pharmacol Ther 1994;56:142-153.
83. Tanaka E, Ishikawa A, Yamamoto Y, Osada A, Tsuji K, Fukao K, et al: Comparison of hepatic drug-oxidizing activity after simultaneous administration of two probe drugs, caffeine and trimethadione, to human subjects. Pharmacol Toxicol 1993;72:31-33.
84. Black C, May G, Csuka ME, Lupoli S, Wilkinson GR, Branch RA: Activity of oxidative routes of metabolism of debrisoquin, mephenytoin, and dapsone is unrelated to the pathogenesis of vinyl chloride-induced disease. Clin Pharmacol Ther 1992;52:659-667.
85. Hägg S, Spigset O, Dahlqvist R: Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 2001;51:169-173.
86. Ministry of Health, Labor, and Welfare: Guidance: Methods for Studying Drug Interactions (Iyakushin 813). Japan: Ministry of Health, Labor, and Welfare, 2001.
87. Kharasch ED, Jubert C, Senn T, Bowdle TA, Thummel KE: Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. J Clin Pharmacol 1999;39:664-669.
88. Neuvonen PJ, Kantola T, Kivistö K: Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998;63:332-341.
89. Sugimoto KI, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K, et al: Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001;70:518-524.
90. Mousa O, Brater DC, Sundblad KJ, Hall SD: The interaction of diltiazem with simvastatin. Clin Pharmacol Ther 2000;67:267-274.
91. Riesenman C, Lam YWF, Ereshefsky L: Intraindividual variability of the dextromephan/dextrophan ratio in extensive metabolizers [abstract]. Clin Pharmacol Ther 1996;59:137.
92. Steiner E, Spina E: Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators. Clin Pharmacol Ther 1987;42:278-282.
93. Weiss P, Halkin H, Almog S: The negative impact of biological variation in the effect and clearance of warfarin on methods for prediction of dose requirement. Thromb Haemost 1986;56(3):371-375.
94. Damkier P, Brosen K: Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6. Clin Pharmacol Ther 2000;68:199-209.
95. Veronese ME, Miners JO, Randles D, Gregov D, Birkett DJ: Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin Pharmacol Ther 1990;47:403-411.
96. Kim MJ, Bertino J, Gaedigk A, Zhang Y, Sellers E, Nafziger AN: Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker. Clin Pharmacol Ther 2002;72:192-199.
97. Christensen M, Tybring G, Mihara K, Yasui-Furokori N, Carrillo JA, Ramos SI, et al: Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther 2002;71:141-152.
98. Simon T, Becquemont L, Hamon B, Nouyrigat E, Chodjania Y, Poirier JM, et al: Variability of cytochrome P450 1A2 activity over time in young and elderly healthy volunteers. Br J Clin Pharmacol 2001;52(5):601-604.
99. Kashuba AD, Bertino JS Jr, Kearns GL, Leeder JS, James AW, Gotschall R, et al: Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping. Clin Pharmacol Ther 1998;63:540-551.
100. Slaughter RL, Goldberg A, Choi L, Adams E, Middleton E Jr: Intraindividual variability in theophylline pharmacokinetics in subjects with mild/moderate asthma. J Allergy Clin Immunol 1987;80(1):33-38.
101. Dreisbach A, Ferencz N, Hopkins NE, Fuentes MG, Rege AB, George WJ, et al: Urinary excretion of 6-hydroxychlorzoxazone as an index of CYP2E1 activity. Clin Pharmacol Ther 1995;58:498-505.
102. Kharasch ED, Thummel KE, Mhyre J, Lillibridge JH: Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1. Clin Pharmacol Ther 1993;53:643-650.